Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Proportion of patients with HBsAg negative.	24 weeks post treatment.
Secondary	Changes of HBsAg level from baseline.	up to 168 weeks.
Secondary	Proportion of patients with HBsAg seroconversion.	up to 168 weeks.
Secondary	Proportion of patients with HBeAg negative.	up to 168 weeks
Secondary	Proportion of patients with HBeAg seroconversion.	up to 168 weeks.
Secondary	Changes of HBeAg level from baseline.	up to 168 weeks.
Secondary	Proportion of patients with HBV DNA undetectable.	up to 168 weeks.
Secondary	Changes of HBV DNA level from baseline.	up to 168 weeks.
Secondary	Proportion of patients with ALT normalization.	up to 168 weeks.
Secondary	Proportion of patients with liver fibrosis.	up to 168 weeks.
Secondary	Proportion of patients with liver cirrhosis.	up to 168 weeks.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04846491/registered